GEN Exclusives

More »

GEN News Highlights

More »
Apr 25, 2013

Scientists Prime “Smartphone-Like” POC Malaria Diagnostic for the Field

  • A European collaboration among researchers at St. George’s University of London, the Karolinksa Institutet, Tubingen University, and nanotech firm QuantuMDx Group working to develop what they call a “smartphone-like” device to analyze the DNA of different malaria strains from just a finger-prick of blood and in just 15 minutes today announced that its prototype device will be ready for field testing this year, well ahead of schedule.

    The group, dubbed the Nanomal Consortium, is working in response to the fear that artemisinin-based combination therapies against malaria will soon become ineffective. Supported by €5.2 million (around $6.77 million) through the European Commission’s Seventh Framework Program, the researchers hope the nanotech-based point-of-care diagnostic device they are developing will help enable the eventual personalized prescription of effective antimalarial drugs.

    “Placing a full malaria screen with drug resistance status based on accurate DNA analysis in the palm of a health professional’s hand will allow instant prescribing of the most effective antimalaria medication for that patient,” QuantuMDx CEO Elaine Warburton said in a statement. “Nanomal’s rapid, low-cost DNA testing will further support the global health challenge to eradicate malaria.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »